IiSGM

L1: Transplantation of hematopoietic progenitor cells.

1.1. Transplantation of nonconventional hematopoietic progenitor cells (haploidentical, dual).

1.2. Transplantation of hematopoietic progenitor cells in patients with AIDS.

1.3. Cell therapy (mesenchymal, NK cells, etc.)

1.4. Follow-up of transplantation of hematopoietic progenitors (genetics and flow cytometry).

1.5. Biomarkers for prediction of post-transplant complications (genetic polymorphism, proteins, etc.).

1.6. Gene/cell therapy with CAR-T cells

L2: Myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome.

2.1. Treatment with next-generation drugs.

2.2. Genomics of the tumour cell.

2.3. In vitro drug resistance studies.

2.4. Cytotoxicity studies with NK.

L3: High-grade lymphomas.

3.1. Liquid biopsy (free DNA in plasma) in high-grade lymphomas.

L4: Chronic myeloid leukemia.

4.1. Studies on discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia.

L5: Genetics of hematologic neoplasms.

5.1. Genetic markers for diagnosis, prognosis and targeted treatment.

5.2. Genomics of hematologic neoplasms: next-generation sequencing.

5.3. Leukemogenesis models.

5.4 Germ genomic alterations

L6: Clinical research (clinical trials).

6.1. Molecular targets in the treatment of hemato-oncology patients.

6.2. Monoclonal antibodies in the treatment of hematology-oncology patients.

6.3. Cell therapy (mesenchymal, NK cells, etc.

6.4. Gene/cell therapy with CAR-T cells

L7: Electronic management of clinical information.

Axis 2: Paediatric hematology-oncology

L1: Hemoglobinopathies. (CSUR de Eritropatología Hereditaria)

1.1 Transplantation of hematopoietic progenitors in hemoglobinopathies

1.2 Clinical monitoring of sickle cell disease from neonatal screening

1.3 Erythrocytapheresis in the Paediatric Sickle Cell Patient

L2: Adjuvant therapy in paediatric hematology-oncology.

L3: Fanconi anemia.

L3.1 Multidisciplinary follow-up in Fanconi’s Anemia

L4: Solid tumours in children.

L5: Leukemia in children.